Additionally, high levels of RBBP4, which appears to be related to poor prognosis of colon cancer with or without hepatic metastasis [125], could be also predictive for poor survival outcome of low-grade glioma (LGG) patients and, therefore, it could be regarded as a potential LGG biomarker and an immunotherapy target [126]. This evidence concerns the gene RBBP4 and colonic neoplasm.